Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

An antimicrobial peptide of the cathelicidin family that provides innate immune defense by killing pathogens and modulating inflammation and wound healing.

Quick Stats
Studies 2230
Trials 95
Formula C205H340N60O53
Clear All
Utility 2
pubmed Feb 21, 2012

Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide.

de la Fuente-Núñez. César C; Korolik. Victoria V; Bains. Manjeet M; Nguyen. Uyen U; B...

Scientists found a tiny synthetic peptide (9 amino acids long) that can stop harmful bacteria from forming protective biofilms at doses far lower than needed to kill the bacteria outright. It works on several nasty bugs, including Pseudomonas, Burkholderia, and Listeria, by messing with their movement and gene activity. While it’s not a ready‑to‑use supplement, it shows that very small, positively‑charged peptides might be a new way to fight chronic infections.

Utility 2
pubmed Oct 18, 2010

LL-37 as a therapeutic target for late stage prostate cancer.

Hensel. Jonathan A JA; Chanda. Diptiman D; Kumar. Sanjay S; Sawant. Anandi A; Grizzle. William E WE;...

Researchers found that the antimicrobial peptide LL-37 (and its mouse version CRAMP) is higher in prostate cancer tissue and that lowering its levels in mouse cancer cells slows their growth, invasion, and blood‑vessel formation, leading to smaller tumors in mice.

Utility 2
pubmed Jun 18, 2009

Burkholderia cenocepacia zinc metalloproteases influence resistance to antimicrobial peptides.

Kooi. Cora C; Sokol. Pamela A PA

The study shows that a bacterial enzyme called ZmpA can break down the human antimicrobial peptide LL‑37, while a related enzyme ZmpB cannot. This means that certain infections could neutralize LL‑37’s natural defense role, which is important if you’re thinking about using LL‑37 as a supplement or therapy.

Utility 2
pubmed Feb 13, 2009

P2X(7) receptor and macrophage function.

Wewers. Mark D MD; Sarkar. Anasuya A

The paper shows that the immune‑boosting peptide LL‑37 can trigger a receptor called P2X7 on macrophages, which then activates an inflammation‑driving complex called the inflammasome, but only after the cells have been ‘primed’ first. It also finds that blocking certain kinases can stop this activation, hinting at ways to control inflammation.

Utility 2
pubmed May 11, 2009

NF-kappaB-dependent induction of cathelicidin-related antimicrobial peptide in murine mast cells by lipopolysaccharide.

Li. Guiming G; Domenico. Joanne J; Jia. Yi Y; Lucas. Joseph J JJ; Gelfand. Erwin W EW

The study shows that in mouse mast cells, the antimicrobial peptide similar to human LL‑37 (called CRAMP) is turned on by the NF‑ÎșB pathway when the cells detect bacterial components, while other signaling routes (MAPKs) don’t matter much. This means that anything that blocks NF‑ÎșB could lower LL‑37 levels and possibly weaken innate immunity, but boosting NF‑ÎșB might raise them.

Utility 2
pubmed Sep 18, 2008

Identification of a novel protein promoting the colonization and survival of Finegoldia magna, a bacterial commensal and opportunistic pathogen.

Frick. Inga-Maria IM; Karlsson. Christofer C; Mörgelin. Matthias M; Olin. Anders I AI; Janjusev...

The study found that a protein called FAF, made by the common skin bacterium Finegoldia magna, helps the bacteria stick to skin layers and form clumps, and importantly, it can block the human antimicrobial peptide LL‑37. This means that the presence of this bacterium could reduce the natural antibacterial action of LL‑37 on the skin.

Utility 2
pubmed Jul 3, 2009

In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides.

Kanthawong. Sakawrat S; Nazmi. Kamran K; Wongratanacheewin. Surasakdi S; Bolscher. Jan G M JG; Wuthi...

Scientists tested ten antimicrobial peptides against the bacteria that causes melioidosis and found that the human peptide LL‑37 killed all 24 bacterial isolates, even those resistant to standard antibiotics. This lab result suggests LL‑37 could become a future treatment, but it’s not yet a usable supplement or protocol for everyday use.

Utility 2
pubmed Oct 21, 2008

Resistance against antimicrobial peptides is independent of Escherichia coli AcrAB, Pseudomonas aeruginosa MexAB and Staphylococcus aureus NorA efflux pumps.

Rieg. Siegbert S; Huth. Anja A; Kalbacher. Hubert H; Kern. Winfried V WV

The study found that common drug‑pumping mechanisms in E. coli, P. aeruginosa and S. aureus don’t help these bacteria dodge the human antimicrobial peptide LL‑37 (or similar peptides). In plain terms, the bacteria’s usual resistance tricks don’t work against LL‑37, so this peptide’s natural killing ability isn’t blocked by those pumps.

Utility 2
pubmed Sep 1, 2009

Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens.

Benincasa. M M; Mattiuzzo. M M; Herasimenka. Y Y; Cescutti. P P; Rizzo. R R; Gennaro. R R

The study shows that sticky sugar‑coats (polysaccharides) made by lung bacteria like Pseudomonas can block the killing power of the natural antimicrobial peptide LL‑37 and similar peptides, meaning these defenses work less well in infections where such sugars are abundant.

Utility 2
pubmed Apr 8, 2008

Oxidized phospholipids as potential molecular targets for antimicrobial peptides.

Mattila. Juha-Pekka JP; Sabatini. Karen K; Kinnunen. Paavo K J PK

The study shows that the antimicrobial peptide LL‑37 (and similar peptides) sticks better to cell membranes that contain a specific oxidized fat molecule called PoxnoPC, even when salt levels are high, while normal salty conditions usually reduce this sticking. This effect depends on a chemical reaction between the peptide and the aldehyde part of PoxnoPC. The findings are mostly basic science and don’t give direct dosing or usage tips for everyday health hacks.

Utility 2
pubmed Jun 24, 2009

SELDI-TOF-MS of gingival crevicular fluid--a methodological approach.

Dommisch. H H; Vorderwülbecke. S S; Eberhard. J J; Steglich. M M; Jepsen. S S

The researchers developed a lab technique to measure the immune peptide LL‑37 (and related peptides) in the fluid around your gums. They found that people with early gum inflammation have higher LL‑37 levels than healthy gums, suggesting it could serve as a marker for early periodontal issues.

Utility 2
pubmed Sep 18, 2008

Antimicrobial effects of H4-(86-100), histogranin and related compounds--possible involvement of DNA gyrase.

Lemaire. Simon S; Trinh. Thuy-Tiên TT; Le. Hoang-Thanh HT; Tang. Shun-Chii SC; Hincke. Maxwell...

Researchers found that two naturally occurring peptides, H4-(86-100) and histogranin (HNr), can kill a range of bacteria as well as the well‑studied antimicrobial peptide LL‑37. They work by blocking a bacterial enzyme called DNA gyrase, and their killing power is boosted by ATP but stopped by metabolic toxins. The study was done in test‑tube experiments, not in people, so it’s not yet a usable supplement or treatment.

Utility 2
pubmed 2008

Antimicrobial host defense in the upper gastrointestinal tract.

Hosaka. Yoshio Y; Koslowski. Maureen M; Nuding. Sabine S; Wang. Guoxing G; Schlee. Miriam M; Sch&#xe...

The study looked at natural antimicrobial proteins in the upper gut and found that the peptide LL‑37 is barely present in the esophagus, stomach, and duodenum, while other defenses like HBD1 and certain defensins are more common. Even though tissue extracts killed bacteria well, they were less effective against Candida, hinting at missing antimicrobial factors.

Utility 2
pubmed Jan 26, 2009

Recombinant adeno-associated virus-based gene transfer of cathelicidin induces therapeutic neovascularization preferentially via potent collateral growth.

Pinkenburg. Olaf O; Pfosser. Achim A; Hinkel. Rabea R; Böttcher. Martina M; Dinges. Claudia C;...

A study in rabbits showed that delivering the gene for the antimicrobial peptide LL‑37 using a viral vector (rAAV) helped grow new side‑branch blood vessels and improve blood flow in a blocked leg, but it didn’t increase tiny capillaries and the effect relied on a specific cell‑signaling pathway.

Utility 2
pubmed Sep 1, 2009

The streptococcal inhibitor of complement (SIC) protects Streptococcus pyogenes from bacteriocin-like inhibitory substance (BLIS) from Streptococcus salivarius.

Minami. Masaaki M; Ohmori. Daisuke D; Tatsuno. Ichiro I; Isaka. Masanori M; Kawamura. Yoshiaki Y; Oh...

The study shows that a friendly mouth bacterium (Streptococcus salivarius) makes a substance (BLIS) that can weaken a defense protein (SIC) used by the harmful throat bug (Streptococcus pyogenes). When SIC is reduced, the natural antimicrobial peptide LL‑37 works better against the bad bacteria. This was seen in lab dishes, not in people.

Utility 2
pubmed Feb 1, 2009

Primate cathelicidin orthologues display different structures and membrane interactions.

Morgera. Francesca F; Vaccari. Lisa L; Antcheva. Nikolinka N; Scaini. Denis D; Pacor. Sabrina S; Tos...

Different versions of the LL‑37 peptide in primates have distinct shapes and how they stick together, which changes how they interact with cell membranes. The monkey version stays as single pieces and can slip deeper into membranes, acting more like a straight‑up antimicrobial. The human version tends to clump together, which reduces its direct killing power but may help it influence host cells.

Utility 2
pubmed Aug 12, 2009

Structure, dynamics and mapping of membrane-binding residues of micelle-bound antimicrobial peptides by natural abundance (13)C NMR spectroscopy.

Wang. Guangshun G

The study shows a new NMR trick that lets scientists see which parts of antimicrobial peptides like LL‑37 stick to cell‑like membranes. It finds that the aromatic phenylalanine spots are especially important for binding, and swapping a key hydrophobic piece for alanine makes the peptide much weaker against bacteria.

Utility 2
pubmed Apr 4, 2006

LL-37, the only human member of the cathelicidin family of antimicrobial peptides.

Dürr. Ulrich H N UH; Sudheendra. U S US; Ramamoorthy. Ayyalusamy A

LL-37 is the only human cathelicidin peptide and works like a tiny, flexible sword that kills germs, calms inflammation, attracts immune cells, and helps wounds heal. It’s made in many parts of the body, from skin to gut to immune cells, and its shape (a helix) is key to how it works. The review gathers what we know about its structure and many roles, pointing out that we still need more basic science to turn this knowledge into real‑world health tricks.

Utility 2
pubmed Oct 4, 2007

Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils.

Zheng. Y Y; Niyonsaba. F F; Ushio. H H; Nagaoka. I I; Ikeda. S S; Okumura. K K; Ogawa. H H

The study shows that the natural peptide LL‑37 can boost several immune actions of neutrophils: it makes them release more inflammation‑signalling IL‑8, produce reactive oxygen species, and release other antimicrobial proteins called alpha‑defensins. These effects happen through known cell‑signalling pathways (p38 and ERK) and likely involve NADPH oxidase and calcium signals.